MTARC1 Rabbit Polyclonal Antibody

MTARC1, full name mitochondrial amidoxime reducing component 1, is a molybdenum cofactor (Moco)-containing oxidoreductase anchored to the outer mitochondrial membrane, with its catalytic domain exposed to the cytoplasm. It functions in concert with its electron transfer partners—cytochrome b5 and NADH-cytochrome b5 reductase—utilizing reducing equivalents from NADH to catalyze the reduction of a variety of N-hydroxylated substrates. The core physiological functions of this protein include participation in the synthesis and regulation of nitric oxide (NO), detoxification metabolism of nitrogen-containing compounds, and serving as an important component of the drug metabolism system by reducing the amidoxime groups of prodrug molecules to enhance their bioavailability. In recent years, MTARC1 has become a research hotspot due to its critical role in liver diseases. Genome-wide association studies (GWAS) have identified a common missense variant (rs2642438, p.Ala165Thr) in its coding gene that is associated with a significantly reduced risk of non-alcoholic fatty liver disease (NAFLD), cirrhosis, and even hepatocellular carcinoma. Animal experiments have demonstrated that knockout of the Mtarc1 gene alleviates hepatic steatosis, inflammation, and fibrosis, with the underlying mechanism potentially involving the regulation of fatty acid uptake and lipid accumulation in hepatocytes. These findings have identified MTARC1 as a novel and highly promising drug target, suggesting that its functional inhibition may offer new therapeutic strategies for metabolic dysfunction-associated steatotic liver disease (MASLD) and related conditions.